openPR Logo
Press release

Prenatal and New-born Genetic Testing Market: Key Players are Roche, Abbott, Berry Genomics, BGI, Bio-Rad Laboratories, Illumina, QIAGEN, Sequenom, Natera, Baebies, Agilent Europe

07-24-2018 12:07 PM CET | Health & Medicine

Press release from: fractovia.org

Prenatal and New-born Genetic Testing Market

Prenatal and New-born Genetic Testing Market

Recently, the University of South Australia created ripples in prenatal and newborn genetic testing market with the introduction of a noninvasive lab-on-a-chip technology. The team of researchers at the university used a tiny microfluid device to isolate fetal cells from maternal blood cells allowing for improved genetic testing. The lab-on-chip integrates laboratory functions on a chip ranging from a few millimeters to a few square centimeters that is being further developed to detect a wide range of genetic abnormalities.

Request for a sample of this research report - https://www.fractovia.org/request-sample/970

It is rather overt that such non-invasive genetic testing is a step forward from amniocentesis or taking a sample of cells from the placenta that could result in a miscarriage. In fact, the emergence of non-invasive prenatal technologies that can determine genetic abnormalities with the help of a simple blood test is becoming an inevitable part of pregnancy. Prenatal and newborn genetic testing market, driven by these changing trends, is thus gathering significant traction.

One of the reasons that prenatal and newborn genetic testing market has registered a profitable trajectory is that women are opting to become pregnant with their first child much later in life than what used to be the average first child bearing age even 50 years back. Many women now spend most their 20s earning a degree and gainful employment than starting a family. However, considering the fact that the quality of eggs in a woman declines with age, older women are more prone to conceive children with genetical defects.

Doctors are increasingly advising pregnant women over 35 years of age to undergo prenatal genetic testing to determine if the child is affected with Down Syndrome or Edward Syndrome beside a host of other genetic ailments that are common among babies born to women older than 35 years. Statistics show that the chances of giving birth to a child with Down Syndrome increases drastically after the age of 35. Besides, fetal genetics screening also helps in detecting split spine defect, cystic fibrosis and sickle cell anemia, all of which can cause physical difficulties and even death in infants. Genetic testing is thus allowing women to make a more informed decision about their pregnancies and prepare for adjustments in case their child is about to be born with special needs, thereby driving prenatal and new-born genetic testing industry outlook.

Browse Full Report @ https://bit.ly/2NzNXqw

Down Syndrome is one of the most predominant genetic defects for which genetic testing is highly recommended. At present, Down syndrome accounts for more than 50% of the prenatal and newborn genetic testing market share. Children with Down Syndrome are born with heart defects and often have poor muscle tone besides other problems like high incidence of leukemia and deafness. Countries like Iceland and Denmark are known to have universal genetic screening and 100% abortion rates for Down Syndrome detected in the fetus. Genetic screening is now being hailed as a means of eradicating Down Syndrome entirely as most well-informed parents who have undertaken genetic screening to determine the health of the fetus have opted not to have a child with the challenges of Down Syndrome.

While genetic screening is catching up across major geographies, the United States dominated prenatal and newborn genetic testing market with a major share in 2017. Accounting for almost 50% of the market share in 2017, the United States is expected to emerge as a pivotal growth ground for prenatal and new-born genetic testing industry over 2018-2024. While technological advancement in the field of genetic testing has been spearheaded in the country due to investment in research and development by noted NIPT organizations like Ariosa Diagnostics (Roche), Bio-Rad, Laboratory Corporation of America, Verinata health and Sequenom, favorable reimbursement policies are also contributing toward the growth of the regional prenatal and newborn genetic testing market.

The rising awareness about the importance of genetic screening and the increase in the number of women choosing to have children later in life have added impetus to prenatal and newborn genetic testing industry. Similar trends have been observed across numerous topographies across the globe, driven by government initiatives to facilitate genetic screening and the increase in the number of medical institution and facilities providing the required technology. As medical technology continues to advance, the expansion of prenatal and newborn genetic testing market is rather inevitable. As per estimates, prenatal and new-born genetic testing industry size is expected to cross $7 billion by 2024.

About Fractovia:

Fractovia.org is one of leading in-house and free news portal. It is fully automated, and operates on a constant premise, interfacing with news sites and offering redesigned breaking features to readers across the globe. Our mission is to offer individuals opportunities for connections with news writers and distributors which they can pursue. We operate by mapping articles pertaining to breaking news, constantly and progressively, against a pre-determined word-based theme, offering important connections to readers and clients, as well as distributors.

Contact Us:

1968 S. Coast Hwy #586,
Laguna Beach CA 92651,
USA

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Prenatal and New-born Genetic Testing Market: Key Players are Roche, Abbott, Berry Genomics, BGI, Bio-Rad Laboratories, Illumina, QIAGEN, Sequenom, Natera, Baebies, Agilent Europe here

News-ID: 1142422 • Views: 290

More Releases from fractovia.org

Non-alcoholic Beer Market Key Players are Heineken, Suntory, Bernard Family Brew …
Owing to a worldwide escalation in the preference for low liquor content beverages, the non-alcoholic beer market size has proliferated at an outstanding pace over the past decade. This has been complemented with the fact that the disposable incomes among the global middle-class population have shot up which has further provided a commendable boost to the overall non-alcoholic beer industry. The rising consolidation and maturation of this business space can
Food Protein Ingredients Market key players are ADM, Cargill, DuPont, Bunge, Mea …
Food protein ingredients market has lately witnessed a profitable trajectory, pertaining to the changing relationship of consumers with food due to increasing urbanization and greater disposable incomes. Taking the rapidly increasing global populace into consideration, which incidentally according to the UN, will surpass 9.5 billion, it is rather obvious that consumption patterns will undergo an eventual change. With the changes that will follow in the dietary preferences, experts anticipate food
Food Enzymes Market Trends 2018 with Key Players of this Industry are BASF, DSM, …
Danish food enzymes market major Chr. Hansen, has recently announced that it will be expanding its West Allis plant that produces enzymes that are freeze-dried and shipped all over the world. The enzymes go into yogurt, cheese, and other food, as well as in animal feed, baby formula, probiotic supplements, and natural dyes. Allegedly, this latest expansion by Hansen to increase the production capacity and add new capabilities to its
Dental Osseointegration Implants Market Major Key Players are Zimmer Biomet, Str …
Having already experienced monetary returns from a slew of imperative collaborations since the last few years, osseointegration implants market has now observed yet another partnership that would help increase its overall remuneration. The reputed American producer of dental equipment consumables, Dentsply Sirona has recently announced a partnership with Zephyr Sleep Technologies. Request for a sample of this research report @ https://www.fractovia.org/request-sample/642 This alliance has been apparently aimed at generating potentially new

All 5 Releases


More Releases for Syndrome

Carcinoid Syndrome Diarrhea Treatment Market
Increasing prevalence of rare carcinoid syndrome diarrhea to boost market growth According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome
Carcinoid Syndrome Diarrhea Treatment Market
Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations,
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape. Gorlin syndrome, also known as nevoid
Familial Chylomicronemia Syndrome Treatment Market
Familial Chylomicronemia Syndrome is a genetic condition characterized by an inability of the body to digest fats mainly triglyceride. In Familial Chylomicronemia Syndrome, the lipoprotein lipase (LPS) is not functional, which is the enzyme that breaks down chylomicrons in the blood. The most distinctive sign of Familial Chylomicronemia Syndrome is the appearance of fatty blood on the skin, mainly owing to high level of fat in the body. People with
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017
ReportsWeb.com published “Gorlin Syndrome Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Original Content: Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape. Gorlin
Global Acute Coronary Syndrome Market
The Acute Coronary Syndrome Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Acute coronary syndrome is one of the serious medical conditions characterized by sudden and reduced flow of blood to the heart. The symptoms of acute coronary syndrome are the same